Last reviewed · How we verify

NCT04721080

Pulmonary Tuberculosis Sequelae in Patients With COPD

Status unknown Last updated 3 March 2021
What this trial tests

trial testing Functional Outcome Measurements in Copd in 150 participants. Status unknown.

Timeline
1 May 2020
Primary endpoint
1 May 2021
1 May 2021

Quick facts

Lead sponsorIzmir Katip Celebi University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 May 2020
Primary completion1 May 2021
Estimated completion1 May 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Izmir Katip Celebi University

Who can join

18 and older, any sex, with Copd or Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is known that there is a complex relationship between tuberculosis and COPD. Post-tuberculosis airway disease or COPD associated with tuberculosis occurs in a significant portion of tuberculosis patients. However, it was observed that mortality rates and exacerbation rates of COPD patients with tuberculosis sequel were higher. However, the effect of tuberculosis sequela on functional outcomes in COPD patients has not been investigated in the studies. The aim of this study is to determine whether the previous tuberculosis sequelae has a functional effect on patients with COPD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Copd

Currently open trials in the same condition.

Other Izmir Katip Celebi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04721080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing